ArticleBMC infectious diseases2026
Usefulness of the combined IFN-γ and IL-2 release test in distinguishing between pulmonary tuberculosis and non-pulmonary tuberculosis.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPulmonary tuberculosis (PTB) is a lung-specific disease caused by Mycobacterium tuberculosis(MTB) infection. Its clinical symptoms and imaging features are non-specific, often leading to misdiagnosis. Therefore, rapid, accurate and low-cost diagnostic methods are crucial for distinguishing PTB from other pulmonary conditions. The interferon-gamma (IFN-γ) release assays is an immunological diagnostic tool with proven value in detecting tuberculosis (TB) infection; however, its specificity in assisting the diagnosis of active TB remains limited. The combined IFN-γ and interleukin-2 (IL-2) release test, targeting MTB-specific cytokines, represents an improvement over traditional IFN-γ release assays, offering increased diagnostic specificity through the simultaneous assessment of multiple cytokine responses. This study aimed to evaluate the diagnostic value of the combined IFN-γ and IL-2 release test in differentiating PTB from other lung diseases.
methodsA retrospective cohort study was conducted involving 309 patients hospitalized in the Respiratory Department of Fuyang People’s Hospital from July 2022 to February 2024. Among the 103 patients with PTB, 78 cases were pathogen confirmed PTB, and 25 cases were Clinically diagnosed PTB, and 206 patients had other lung diseases. Cytokine levels were measured using enzyme-linked immunosorbent assay (ELISA). Data analysis was performed with SPSS 26.0 and Graphpad Prism 9.0 software.
resultsThe sensitivity of the combined IFN-γ and IL-2 release test for diagnosing PTB was 85.4%, with a specificity of 85.0% and an area under the curve (AUC) of 0.942. Specificity differed according to disease type, with 80.4% for pneumonia, greater than 90% for lung cancer, non-tuberculous mycobacterial (NTM) lung disease, and chronic obstructive pulmonary disease (COPD), and above 80% for bronchitis. Notably, the double-positive specificity reached 95.6% for other lung diseases.
conclusionThe MTB-specific combined IFN-γ and IL-2 release test demonstrates high sensitivity and specificity, providing valuable diagnostic support for distinguishing PTB from other pulmonary diseases, and holds significant clinical value for identifying PTB. CLINICAL TRAIL NUMBER: Not applicable.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.